Bristol Myers Reports Preliminary Phase 3 Findings Of KarXT Treatment From 12-Week Open-Label Period Of ADEPT-1 Study And 52-Week OLE ADEPT-3 Study In Patients With Psychosis Associated With Alzheimer’s Disease
Benzinga Newsdesk 1 day ago
News
Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baselinePreliminary findings from the ADEPT-3 52-week open-label extension
Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baseline
Preliminary findings from the ADEPT-3 52-week open-label extension provide initial encouraging long-term safety and tolerability data, with symptom score improvements observed
Bristol Myers Squibb (NYSE:BMY) today announced preliminary Phase 3 findings of short- and long-term KarXT treatment from the 12-week open-label period of the ADEPT-1 study and the 52-week open-label extension (OLE) ADEPT-3 study in patients with psychosis associated with Alzheimer’s disease. In both studies, treatment with xanomeline and trospium chloride (KarXT) was associated with improvements in clinician-observed scores of hallucinations and delusions and overall disease severity. KarXT was generally well tolerated across both studies with no new safety signals identified.
These preliminary findings represent the first disclosure of clinical data from the Phase 3 ADEPT program, and were shared today in an oral presentation (Abstract #OC21) at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Massachusetts. The ADEPT trials remain ongoing, and data from the double-blind treatment periods in all ADEPT studies remain blinded.
Participants who completed or prematurely discontinued the respective open-label period were included for analysis; those who were still ongoing at the time of data cutoff were excluded from the analysis. The findings reported are based on descriptive analyses.
